What is HC Wainwright’s Estimate for VERA Q2 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Vera Therapeutics in a report issued on Monday, May 5th. HC Wainwright analyst A. He forecasts that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $3.30 EPS and FY2029 earnings at $5.37 EPS.

A number of other research analysts also recently weighed in on VERA. Wedbush lowered their target price on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective on the stock. Guggenheim upped their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald decreased their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics currently has an average rating of “Buy” and a consensus price target of $63.80.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $22.62 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -8.67 and a beta of 1.28. The business’s fifty day moving average price is $24.48 and its 200-day moving average price is $34.98.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the firm earned ($0.56) EPS.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Huntington National Bank purchased a new stake in Vera Therapeutics in the 4th quarter worth $26,000. AlphaQuest LLC bought a new position in shares of Vera Therapeutics in the fourth quarter worth about $34,000. GF Fund Management CO. LTD. purchased a new stake in shares of Vera Therapeutics during the fourth quarter worth about $56,000. KBC Group NV raised its stake in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after purchasing an additional 1,387 shares during the period. Finally, Summit Investment Advisors Inc. lifted its holdings in Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after purchasing an additional 639 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.